Introduction {#Sec1}
============

Osteoporosis is one of the most common health problems in older people, and its consequence, fragility fractures, can have large impacts on the patient and their family \[[@CR1]\]. There is an increasing recognition of the need to intervene in patients at high risk of fracture to decrease this fracture burden. The FRAX® tool, developed by researchers at the University of Sheffield, is used to evaluate individual fracture risk, based on models that integrate clinical risk factors with or without additional information provided by bone mineral density (BMD) at the femoral neck \[[@CR2]\]. It is freely and easily accessible to healthcare workers with internet access ([www.sheffield.ac.uk/FRAX](http://www.sheffield.ac.uk/FRAX)) and is also available as a paid for application on smartphones. Individual data input and analysis takes less than 1 min. FRAX calculates the 10-year probability of hip fracture alone and of a major osteoporotic fracture (clinical spine, forearm, hip, or shoulder fracture) in patients between 40 and 90 years of age. First released in 2008, FRAX currently has models calibrated for 63 countries, comprising 69 populations (China, Singapore, and the USA have several ethnic-specific models) and is available in 34 languages (Chinese and Portuguese have 2 difference versions).

Whereas FRAX generates numerical fracture probabilities, guidance is needed over the interpretation of these numbers so that its clinical utility is driven by its incorporation into clinical guidelines. To date, FRAX has been accepted in many osteoporosis guidelines in many regions of the world \[[@CR3]--[@CR7]\]. Given disparities in fracture incidence, health policy, and budgetary priorities, there is no international consensus on FRAX thresholds either for the use of BMD or an intervention threshold to be used as an indicator for treatment. In Thailand, FRAX was first mentioned in a guideline launched in 2010 \[[@CR8]\], wherein a FRAX calculation was recommended when the femoral neck BMD T-score was between − 1.0 and − 2.5, and osteoporosis treatment initiated if the 10-year probability of fracture at hip was ≥ 3% or major osteoporosis fracture ≥ 20%, mirroring recommendations from the USA \[[@CR9]\]. In 2010, in the absence of a Thailand-specific FRAX model, it was recommended to use the US Asian or Japanese models. Subsequently, a model for Thailand was released in May 2013, but a new guideline was not published until the end of 2016 \[[@CR6]\]. In this latest guideline, there are several indications for the initiation of pharmacological treatment of osteoporosis. In general, for postmenopausal osteoporosis and male idiopathic osteoporosis age over 50 years, the indication can be one of the following: presentation with a hip or vertebral fracture from low-energy injury; lumbar spine BMD or femoral neck BMD or total hip BMD showing T-score ≤ − 2.5; 10-year probability of hip fracture by FRAX using Thai model (with BMD or without) ≥ 3%.

The primary objective of this study was to assess the access of the online FRAX tool from Thailand and other countries across the period from 2010 to the end of 2018. A secondary objective was to determine, if possible, the impact of guideline incorporation in Thailand on FRAX usage.

Methods {#Sec2}
=======

This is a retrospective descriptive study using a free tool, Google Analytics (<https://analytics.google.com/analytics/web/>) \[[@CR10], [@CR11]\], to document access of users worldwide to the FRAX calculator website. The survey of usage was conducted between 15 February 2010 (the earliest date available in this version of Google Analytics) and 31 December 2018. Data tables were exported from Google Analytics in XLSX format for further analysis. In Analytics, a session is the period of time a user is actively engaged with FRAX tool website. All usage data are associated with a session, whereas a bounce rate captures the percentage of visits in which a person leaves a FRAX website from the landing page without browsing any further, i.e., enter and then leave the FRAX website without a fracture risk calculation. The number of sessions per 1000 population was calculated from the total number of sessions divided by the population size and multiplied by 1000. An estimate of actual FRAX "usage sessions" was calculated from the total session multiplied by 1-bounce rate. The most recent Thai population data in 2017 were acquired from the Bureau of Registration Administration of Thailand \[[@CR12]\]. FRAX usage was assessed in Thailand and compared with patterns of use elsewhere in the world. The land area and approximate 2018 population for each country were acquired from the latest United Nations Population Division estimates, with permission \[[@CR13]\]. All graphs and table were made using the Microsoft office 2016 package (Microsoft WA, USA). Pearson correlation statistics were analysed using IBM SPSS version 18.0 (SPSS Inc., Chicago, Illinois, USA).

Results {#Sec3}
=======

Usage of FRAX tool in Thailand {#Sec4}
------------------------------

Thailand currently comprises 77 regions altogether (76 provinces + Bangkok metropolitan). In the time period studied here (15 February 2010--31 December 2018 inclusive), the first two sessions of access to FRAX from Thailand, recorded in this version of Google Analytics, were on 2 July 2010 from Bangkok and Khon Kaen. Within 2010, FRAX had been accessed from 17 of the Thailand regions and this increased rapidly to a plateau of 69--71 regions in 2014 (Fig. [1](#Fig1){ref-type="fig"}). The highest number of FRAX sessions arose from Bangkok, followed by Khon Kaen and Chiang Mai (Table [1](#Tab1){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). The number of sessions rose steadily from 2010 to 2016, with an approximate seven-fold increase over this time, reflecting an average increase in session rate of 1098 per year. In 2017, there was an apparent acceleration in FRAX session access so that over the last two years there has been an average increase of 4079 sessions per year. In terms of sessions recorded on the FRAX website during the period of this study, Thailand is ranked 35 out of 239 countries or dependencies (Table [2](#Tab2){ref-type="table"}). A fully detailed account of FRAX access from Thailand since 2010 is provided in Supplementary Table [1](#MOESM1){ref-type="media"}.Fig. 1Graph showing the number of Thailand provinces (77 provinces in total) accessing FRAX and the number of total sessions of FRAX accessed from Thailand, recorded per year during the current analysis period (2010--2018)Table 1The top ten Thailand provinces accessing the FRAX tool between February 2010 and December 2018, rank by FRAX usage sessionRankRegion (province)Sessions2017 populationSession per 1000 populationBounce rateFRAX usage sessionsFRAX usage session per 1000 population1Bangkok41,3835,682,4157.350.4%20,5213.62Khon Kaen36941,805,9102.035.2%23941.33Chiang Mai35821,746,8402.149.6%18061.04Chon Buri21101,509,1251.452.0%10130.75Songkhla13221,424,2300.952.5%6280.46Nonthaburi8341,229,7350.745.9%4510.47Phitsanulok745865,3680.946.9%3960.58Nakhon Ratchasima7662,639,2260.352.4%3650.19Nakhon Pathom638911,4920.747.3%3360.410Samut Prakan6881,310,7660.553.5%3200.2Fig. 2Google Analytics output of FRAX access and usage across cities in Thailand over the period of the study (2010--2018). The size of the circle reflects the number of usage episodes recordedTable 2The top ten countries plus Thailand accessing the FRAX tool between February 2010 and December 2018, rank by FRAX usage sessionRankCountrySessions2018 populationSessions per 1000 populationBounce rateFRAX usage sessionsFRAX usage sessions per 1000 population1USA8,048,970326,766,74824.647.1%4,258,34413.02UK2,119,47166,573,50431.837.8%1,317,75519.83Canada646,60736,953,76517.548.5%332,8759.04Spain476,64046,397,45210.343.8%268,0525.85Slovenia269,8292,081,260129.613.8%232,647111.86Japan476,069127,185,3323.756.9%205,4011.67France312,77865,233,2714.841.6%182,7942.88Sweden265,2609,982,70926.635.4%171,25017.29Brazil252,299210,867,9541.234.0%166,4910.810Belgium280,15611,498,51924.448.8%143,42612.535Thailand62,35369,183,1730.949.3%31,6170.5

Worldwide usage of FRAX tool {#Sec5}
----------------------------

Usage of FRAX elsewhere in the world was assessed to provide a context for activity in Thailand. Over the period of this study, 228 countries or dependencies worldwide had documented access and interacted with the FRAX tool website. As previously reported, the country with the most frequent access to the FRAX tool website is the USA \[[@CR14]\]. Over the reporting period, around 4.3 million usage sessions were conducted from the USA, followed by the UK (1.3 million) and Canada (0.3 million) (Table [2](#Tab2){ref-type="table"}). Overall, the correlation (*r*) between usage session number and land area was low (*r* = 0.374, *p* \< 0.001) and that with population size lower still (*r* = 0.164, *p* = 0.011). When usage was adjusted for population size, Slovenia showed the highest usage of FRAX (112 usage sessions per 1000 population), followed by Bermuda (91 usage sessions per 1000 population) and Malta (70 usage sessions per 1000 population). Within the top ten countries for absolute numbers of usage sessions listed in Table [2](#Tab2){ref-type="table"}, following Slovenia, the highest rates adjusted for the population were seen in the UK and Sweden. The lowest usage session rate was seen in Brazil (0.8 usage session per 1000 population) and an even lower rate was recorded from Thailand (0.5 usage per 1000 population). A fully detailed account of FRAX access from all countries since 2010 is provided in Supplementary Table [2](#MOESM2){ref-type="media"}.

Discussion {#Sec6}
==========

Like the developed world in general, Thailand is moving rapidly towards an aged society. It is estimated that in 2021, 13 million of the total 65 million population (i.e., 20%) will comprise men and women aged 60 years and older; by 2031 \[[@CR15]\], it is predicted that this will rise to 28% of the total population. The impact that this will have for the burden of fractures has meant that osteoporosis is now recognised in national health policy in Thailand in 2018, under a campaign of "refracture prevention" that promotes secondary fracture prevention but also embraces osteoporosis screening and treatment \[[@CR16]\]. Given the low availability of DXA and its relatively high associated costs (approximately US\$ 60 for both lumbar spine and hip scans), it is highly unlikely that a campaign with DXA as the first line tool in Thailand would be achievable. In the UK and other European guidance, clinical risk assessment by the FRAX tool is advocated as the first line, with DXA measured BMD targeted to those who lie close to an intervention threshold \[[@CR3], [@CR17]\]. Such an approach shows a more economic use of scanning resources \[[@CR18]\]. The pattern of FRAX usage over time in Thailand is interesting. For the first 2--3 years of the study period, a Thailand-specific model of FRAX was not available and users were advised to undertake calculations using the Japanese or US Asian tool \[[@CR8], [@CR19]\]. It is notable that the number of regions accessing FRAX increased quite dramatically in 2013, coinciding with, but perhaps unrelated to, the launch of the Thailand FRAX model. As noted above, the more rapid increase in actual FRAX usage occurred in line with updated guidance and a greater focus on the burden of osteoporosis in 2016/2017 \[[@CR6]\]. Importantly, this new osteoporosis management guideline advocated the use of FRAX as a potential gateway to treatment; even in the absence of a DXA BMD measurement, as in menopausal woman and men aged over 50 years old, therapy can be indicated by a 10-year FRAX Thailand model probability of hip fracture of 3.0% or greater. Of note, a recent study in the UK that used FRAX as a population screening tool, in combination with appropriate intervention in those at high risk of hip fracture, showed a 28% reduction in hip fracture \[[@CR17], [@CR20]\].

This retrospective descriptive study shows that the FRAX website--based tool is accessed worldwide. As expected, this access varies considerably from country to country; the finding that land area and, more importantly, population size are only relatively weakly correlated with usage suggests that other factors impact on FRAX website access. Awareness of osteoporosis, availability of resources, and the priority of fracture burden as a local or national healthcare concern are also likely to be of importance. For example, the availability of DXA equipment, if regarded as a surrogate measure of the awareness of osteoporosis and its priority, might be expected to relate to FRAX usage; Slovenia, the highest user based on population size, also has one of the highest concentrations of DXA scanners with 20 per million of the population compared with for example the UK (8.2 per million) \[[@CR21]\]. In Thailand, where DXA provision is even more limited (0.67 scanners per million) \[[@CR22]\], the FRAX usage is also much lower. It is of interest, however, that FRAX usage in Thailand is growing and the potential reasons for this are undoubtedly of interest; our observation of an approximately 4-fold increase in annual growth rates for FRAX access that followed the launch of new national guidelines in late 2016 suggest that national initiatives and specific guidance on FRAX's role in risk assessment and management can enhance its usage.

Our study has some limitations. Firstly, the data from Google Analytics records access to the website, not the actual fracture risk calculation. Nonetheless, the session rate will still provide information on the pattern of use over time and across geographies. We have tried to remove accidental or transient site access by also analysing the sessions adjusted for the bounce rate; the patterns are similar though the absolute number of sessions is decreased. As the website counter embedded on the FRAX website actually documents full calculations, we have been able to estimate that there is an approximate ratio of 2.7 between actual calculations and usage (non-bounce) sessions. There is of course the possibility that the use of the online FRAX calculator may be for purposes other than patient evaluation and clinical care, for example, research or other academic purposes. However, it is likely that there is a correlation between clinical and research use within particular countries. A further point in the interpretation of high usage per capita is the impact of the overall population size; for example, the populations of Bermuda and Malta are relatively small, ranging from approximately 60,000--400,000, so that the adoption of FRAX by a relatively small number of clinicians can have a significant impact on the per capita use. Finally, the website is only one source of access to FRAX calculations; those conducted on densitometers or by a smartphone app or paper-based systems will not be included in our analysis.

Conclusion {#Sec7}
==========

The FRAX online tool is widely accessed across the world. In Thailand, the use of FRAX has steadily increased over the period 2010--2018. A more rapid increase in the last 2 years suggests that its incorporation into national guidance in 2016 enhanced its usage. Further national initiatives to promote awareness should be strongly considered.
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